Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Melanoma 3Pancreatic Neoplasms 2Gliosarcoma 2Glioma 2Glioblastoma 2Breast Neoplasms 2Brain Neoplasms 2Recurrence 1Neoplasms 1Neoplasm Metastasis 1Medulloblastoma 1Lung Neoplasms 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Temozolomide 2Etoposide 2Erlotinib Hydrochloride 2pomalidomide 1dostarlimab 1dinutuximab 1cemiplimab 1bempegaldesleukin 1abemaciclib 1Valacyclovir 1Radiotherapy 1Radiation 1Prodrugs 1Pemetrexed 1ONC206 1Nivolumab 1Irinotecan 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fentanyl 1Cyclophosphamide 1CLR1404 190Y-octreotide, DOTA-Tyr(3)- 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Ependymoma × 1-methyltryptophan × Clear all
NCT02502708 2020-06-04

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Lumos Pharma

Phase 1 Completed
81 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡